Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer

Akira Matsui; Masahiro Morise; Ichidai Tanaka; Sachiko Ozone; Reiko Matsuzawa; Junji Koyama; Tetsunari Hase; Naozumi Hashimoto; Mitsuo Sato; Yoshinori Hasegawa

doi:10.1080/07357907.2020.1793350

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer

Akira Matsui, Masahiro Morise, Ichidai Tanaka, Sachiko Ozone, Reiko Matsuzawa, Junji Koyama, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa

Research output: Contribution to journal › Article › peer-review

Abstract

In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10–20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.

Original language	English
Pages (from-to)	424-430
Number of pages	7
Journal	Cancer Investigation
Volume	38
Issue number	7
DOIs	https://doi.org/10.1080/07357907.2020.1793350
Publication status	Published - 08-08-2020
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/07357907.2020.1793350

Cite this

@article{7020e9d03f7b431bb19cb51642a06509,

title = "Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer",

abstract = "In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10–20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.",

author = "Akira Matsui and Masahiro Morise and Ichidai Tanaka and Sachiko Ozone and Reiko Matsuzawa and Junji Koyama and Tetsunari Hase and Naozumi Hashimoto and Mitsuo Sato and Yoshinori Hasegawa",

note = "Publisher Copyright: {\textcopyright} 2020 Taylor & Francis Group, LLC.",

year = "2020",

month = aug,

day = "8",

doi = "10.1080/07357907.2020.1793350",

language = "English",

volume = "38",

pages = "424--430",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor & Francis Group LLC Philadelphia",

number = "7",

}

TY - JOUR

T1 - Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer

AU - Matsui, Akira

AU - Morise, Masahiro

AU - Tanaka, Ichidai

AU - Ozone, Sachiko

AU - Matsuzawa, Reiko

AU - Koyama, Junji

AU - Hase, Tetsunari

AU - Hashimoto, Naozumi

AU - Sato, Mitsuo

AU - Hasegawa, Yoshinori

PY - 2020/8/8

Y1 - 2020/8/8

N2 - In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10–20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.

AB - In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10–20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.

UR - http://www.scopus.com/inward/record.url?scp=85088876164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088876164&partnerID=8YFLogxK

U2 - 10.1080/07357907.2020.1793350

DO - 10.1080/07357907.2020.1793350

M3 - Article

C2 - 32643445

AN - SCOPUS:85088876164

SN - 0735-7907

VL - 38

SP - 424

EP - 430

JO - Cancer Investigation

JF - Cancer Investigation

IS - 7

ER -

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this